Bethesda, MD (PRWEB) July 23, 2013
Patient advocates, industry leaders, researchers, regulatory officials, investors and thought leaders dedicated to advancing the development of and access to therapies for rare diseases will come together for the third annual U.S. Conference on Rare Diseases and Orphan Products, held in Bethesda, Oct. 7–9. The conference is hosted by DIA and the National Organization for Rare Disorders (NORD).
The Affordable Care Act and the U.S. Food and Drug Administration (FDA) Safety and Innovation Act give new urgency to the topics, and discussions will address questions such as: What is the impact of new regulatory statutes on the rare disease community? What is the investment outlook for orphan product development? What will our health care system look like in the coming months and years?
“These are crucial times for the rare disease community, as regulation is shaping the future of drug development and access,” said Peter L. Saltonstall, NORD president and CEO. “This conference provides an unparalleled opportunity to share expert insight and collaborate in ways that are vital for the nearly 30 million Americans living with rare diseases, and many others worldwide.”
The conference, hosted in collaboration with FDA and EURORDIS (Rare Diseases Europe), will include keynote, plenary, and group sessions organized by four central themes: research and regulation; access and reimbursement; the role of the patient in research and regulatory processes; and implementation of the Affordable Care Act.
This year marks the 30th anniversary of NORD and the Orphan Drug Act, which provided federal financial incentives that have made it possible for companies to develop treatments for people with rare diseases.
“With DIA’s established reputation for bringing together thought leaders to promote progress, and NOR
Copyright©2012 Vocus, Inc.
All rights reserved